Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib

Area of Science:

• Pulmonology
• Pharmacology
• Fibrosis Research

Background:

• Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with limited treatment options.
• Current treatments may benefit from combination therapies for synergistic effects.
• Phosphodiesterase type 5 inhibitors (PDE5-Is) are explored for IPF beyond their vascular effects.

Purpose of the Study:

• To evaluate vardenafil's effect on fibroblast extracellular matrix (ECM) generation and epithelial-mesenchymal transformation (EMT).
• To assess the synergistic effect of vardenafil combined with nintedanib on ECM accumulation.
• To investigate vardenafil's efficacy in a bleomycin-induced mouse model of lung fibrosis.

Main Methods:

• In vitro studies using fibroblasts treated with vardenafil to assess ECM generation and signaling.
• Fibronectin enzyme-linked immunosorbent assay (ELISA) to evaluate synergistic ECM suppression by vardenafil and nintedanib.
• In vivo experiments using a bleomycin mouse model to assess vardenafil's antifibrotic effects and survival.

Main Results:

• Vardenafil alone suppressed fibroblast-driven ECM generation in vitro.
• Vardenafil demonstrated significant synergistic suppression of ECM when combined with nintedanib.
• Vardenafil treatment improved fibrosis markers and increased survival in bleomycin-treated mice.

Conclusions:

• Vardenafil exhibits potential as a therapeutic agent for IPF, both as a monotherapy and in combination with nintedanib.
• The findings suggest vardenafil's ability to reduce ECM accumulation and mitigate fibrosis progression.
• Further research is warranted to confirm vardenafil's efficacy and safety in clinical settings for IPF treatment.